vs
Side-by-side financial comparison of Bio-Techne (TECH) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $295.9M, roughly 1.1× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -18.0%, a 30.8% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -76.3%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -4.6%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
TECH vs WH — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $334.0M |
| Net Profit | $38.0M | $-60.0M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | — |
| Net Margin | 12.8% | -18.0% |
| Revenue YoY | -6.4% | -76.3% |
| Net Profit YoY | 68.3% | -170.6% |
| EPS (diluted) | $0.24 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $295.9M | $334.0M | ||
| Q3 25 | — | $382.0M | ||
| Q2 25 | $317.0M | $397.0M | ||
| Q1 25 | $316.2M | $316.0M | ||
| Q4 24 | $297.0M | $336.0M | ||
| Q3 24 | $289.5M | $396.0M | ||
| Q2 24 | $306.1M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $38.0M | $-60.0M | ||
| Q3 25 | — | $105.0M | ||
| Q2 25 | $-17.7M | $87.0M | ||
| Q1 25 | $22.6M | $61.0M | ||
| Q4 24 | $34.9M | $85.0M | ||
| Q3 24 | $33.6M | $102.0M | ||
| Q2 24 | $40.6M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 18.4% | -11.4% | ||
| Q3 25 | — | 46.6% | ||
| Q2 25 | -7.5% | 37.8% | ||
| Q1 25 | 12.2% | 35.4% | ||
| Q4 24 | 16.0% | 38.4% | ||
| Q3 24 | 13.8% | 43.2% | ||
| Q2 24 | 15.0% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 12.8% | -18.0% | ||
| Q3 25 | — | 27.5% | ||
| Q2 25 | -5.6% | 21.9% | ||
| Q1 25 | 7.1% | 19.3% | ||
| Q4 24 | 11.7% | 25.3% | ||
| Q3 24 | 11.6% | 25.8% | ||
| Q2 24 | 13.3% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.24 | $-0.77 | ||
| Q3 25 | — | $1.36 | ||
| Q2 25 | $-0.11 | $1.13 | ||
| Q1 25 | $0.14 | $0.78 | ||
| Q4 24 | $0.22 | $1.06 | ||
| Q3 24 | $0.21 | $1.29 | ||
| Q2 24 | $0.26 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $64.0M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $468.0M |
| Total Assets | $2.5B | $4.2B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $172.9M | $64.0M | ||
| Q3 25 | — | $70.0M | ||
| Q2 25 | $162.2M | $50.0M | ||
| Q1 25 | $140.7M | $48.0M | ||
| Q4 24 | $177.5M | $103.0M | ||
| Q3 24 | $187.5M | $72.0M | ||
| Q2 24 | $152.9M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $346.0M | $2.5B | ||
| Q1 25 | $330.0M | $2.5B | ||
| Q4 24 | $300.0M | $2.4B | ||
| Q3 24 | $300.0M | $2.4B | ||
| Q2 24 | $319.0M | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $2.0B | $468.0M | ||
| Q3 25 | — | $583.0M | ||
| Q2 25 | $1.9B | $570.0M | ||
| Q1 25 | $2.0B | $579.0M | ||
| Q4 24 | $2.1B | $650.0M | ||
| Q3 24 | $2.1B | $583.0M | ||
| Q2 24 | $2.1B | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $2.5B | $4.2B | ||
| Q3 25 | — | $4.3B | ||
| Q2 25 | $2.6B | $4.3B | ||
| Q1 25 | $2.6B | $4.2B | ||
| Q4 24 | $2.7B | $4.2B | ||
| Q3 24 | $2.7B | $4.2B | ||
| Q2 24 | $2.7B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | 0.18× | 4.44× | ||
| Q1 25 | 0.16× | 4.29× | ||
| Q4 24 | 0.14× | 3.72× | ||
| Q3 24 | 0.14× | 4.19× | ||
| Q2 24 | 0.15× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $367.0M |
| Free Cash FlowOCF − Capex | — | $168.0M |
| FCF MarginFCF / Revenue | — | 50.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | — | $152.0M | ||
| Q3 25 | — | $86.0M | ||
| Q2 25 | $98.2M | $70.0M | ||
| Q1 25 | $41.1M | $59.0M | ||
| Q4 24 | $84.3M | $134.0M | ||
| Q3 24 | $63.9M | $79.0M | ||
| Q2 24 | $75.5M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | — | $75.0M | ||
| Q2 25 | $93.3M | $58.0M | ||
| Q1 25 | $31.0M | $52.0M | ||
| Q4 24 | $77.5M | $109.0M | ||
| Q3 24 | $54.7M | $71.0M | ||
| Q2 24 | $57.5M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | — | 40.7% | ||
| Q3 25 | — | 19.6% | ||
| Q2 25 | 29.4% | 14.6% | ||
| Q1 25 | 9.8% | 16.5% | ||
| Q4 24 | 26.1% | 32.4% | ||
| Q3 24 | 18.9% | 17.9% | ||
| Q2 24 | 18.8% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | 1.5% | 3.0% | ||
| Q1 25 | 3.2% | 2.2% | ||
| Q4 24 | 2.3% | 7.4% | ||
| Q3 24 | 3.2% | 2.0% | ||
| Q2 24 | 5.9% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | 1.82× | 0.97× | ||
| Q4 24 | 2.42× | 1.58× | ||
| Q3 24 | 1.90× | 0.77× | ||
| Q2 24 | 1.86× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
